Titration and discontinuation of semaglutide for weight management in commercially insured US adults
Xu Y, Carrero J, Chang A, Inker L, Zhang D, Mukhopadhyay A, Blecker S, Horwitz L, Grams M, Shin J. Titration and discontinuation of semaglutide for weight management in commercially insured US adults. Obesity 2025, 33: 1243-1248. PMID: 40464214, DOI: 10.1002/oby.24315.Peer-Reviewed Original ResearchConceptsDose escalation scheduleHigher discontinuation rateDiscontinuation ratesWeight managementMultivariate Cox regressionUS adultsAssociated with discontinuationCommercially insured adultsEarly discontinuationAssociated with low household incomeCox regressionSemaglutideLowest quintileHighest quintileDelivery of evidence-based careLower household incomeMonthsEvidence-based careCopayment amountQuintileAdultsReduce financial barriersDiscontinuationEducation levelIdentified factors
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply